Eupraxia Pharmaceuticals (EPRX) Investor presentation summary

Study design and administration

• RESOLVE is a Phase 1b/2 multicenter, open-label, dose-escalation trial evaluating EP-104GI in EoE patients.

• Single administration of EP-104GI was delivered via submucosal injection during endoscopy, with escalating doses and injection sites.

• Dose cohorts ranged from 4×1 mg to 20×8 mg, with ongoing optimization in higher dose groups.

Pharmacokinetics and safety

• Plasma fluticasone concentrations remained near constant and ≤100 pg/mL over 36–52 weeks after administration.

• EP-104GI was generally safe and well tolerated, with no clinically significant adrenal suppression, glucose derangement, or dose-limiting toxicity.

• Most adverse events were typical of endoscopy procedures.

Efficacy and histological outcomes

• Dose escalation led to persistent improvements in EoE histopathology over 36 weeks, with EoEHSS grade reductions from -23% to -88% and stage reductions from -14% to -90%.

• Both inflammatory and structural features of EoE improved, with the largest gains in the highest dose cohorts (83–94% improvement at week 36).

• Consistent reductions in peak eosinophil counts were observed, with more biopsies achieving PEC ≤6/hpf at higher doses.